 |
|
Hidden heart condition increases the risk of death in patients waiting for kidney transplants
May 16, 2008An often asymptomatic condition-systolic dysfunction, or decreased pumping of the heart-poses an increased risk of death for patients on kidney transplant waiting lists, according to a study appearing in the June 2008 issue of the Journal of the American Society Nephrology (JASN). The findings reveal that a clinical indicator beyond well-known risk factors for cardiovascular mortality should be considered when caring for patients waiting for kidney donations. The study also suggests that changes in organ allocation policies may be warranted.
Previous research has shown that patients with chronic kidney disease face an elevated risk of dying from heart conditions, such as cardiac ischemia, which occurs when the heart receives an insufficient supply of blood and oxygen. However, ischemic events do not account for most of the cardiac deaths that have been reported in these patients.
To determine what other heart effects may be playing a role in the deaths of patients with chronic kidney disease, Dr. Angelo M. de Mattos, an associate professor of nephrology at the University of California, Davis, School of Medicine and Medical Center in Sacramento, Calif., and colleagues at the University of Alabama at Birmingham analyzed the records for 2,718 kidney transplant candidates, noting the causes of death in those who died. During the study, 681 patients died during follow-up, which was conducted for a median of 27 months.
The investigators discovered that patients with systolic dysfunction were nearly twice as likely to die as those without this condition. This higher rate of mortality was similar to that seen in patients with cardiac ischemia, the most well-known risk factor for cardiovascular death in patients with chronic kidney disease.
Dr. de Mattos and his team found that death rates for patients with systolic dysfunction who were waiting for kidney transplants were almost six-fold higher than the reported mortality for individuals with systolic dysfunction in the general population.
The study "identifies a subset of the chronic kidney disease population (those with systolic dysfunction, with or without ischemia) at significantly higher mortality risk while awaiting transplantation, where the role of medical interventions and devices such as implantable cardiac defibrillators and pacemakers should be studied," the authors write. Widely available and minimally invasive testing could be used to help identify those patients with chronic kidney disease who have this mostly asymptomatic, yet life-threatening, condition.
The authors note that if their findings are supported by additional studies, organ distribution policies may need to be redesigned so as to place a priority on these individuals who traditionally have not been considered at an increased risk of death.
American Society of Nephrology
The investigators discovered that patients with systolic dysfunction were nearly twice as likely to die as those without this condition. This higher rate of mortality was similar to that seen in patients with cardiac ischemia, the most well-known risk factor for cardiovascular death in patients with chronic kidney disease.
Dr. de Mattos and his team found that death rates for patients with systolic dysfunction who were waiting for kidney transplants were almost six-fold higher than the reported mortality for individuals with systolic dysfunction in the general population.
The study "identifies a subset of the chronic kidney disease population (those with systolic dysfunction, with or without ischemia) at significantly higher mortality risk while awaiting transplantation, where the role of medical interventions and devices such as implantable cardiac defibrillators and pacemakers should be studied," the authors write. Widely available and minimally invasive testing could be used to help identify those patients with chronic kidney disease who have this mostly asymptomatic, yet life-threatening, condition.
The authors note that if their findings are supported by additional studies, organ distribution policies may need to be redesigned so as to place a priority on these individuals who traditionally have not been considered at an increased risk of death.
American Society of Nephrology
Systolic Dysfunction Current Events and Systolic Dysfunction News RSSScreening for left ventricular dysfunction may have less value than thought
The value and cost-effectiveness of screening for left ventricular (LV) dysfunction remains unclear, particularly since specific, evidence-based treatments are not available for the majority of patients with preserved systolic dysfunction.
Sleep apnea may not be closely linked to heart failure severity
Obstructive sleep apnea (OSA) and central sleep apnea (CSA) are not markedly decreased in heart failure (HF) patients managed with beta-blockers and spironolactone.
Metabolic syndrome points to heart health
Typified by high blood pressure, weight gain around the waist and problems regulating blood sugar, metabolic syndrome may also be associated with compromised heart structure and function.
Most hospital performance measures for heart failure not linked to improved patient outcomes
Four of five hospital performance measures for heart failure do not appear to accurately reflect the quality of care provided.
A simple, noninvasive test measures survival time in adult pulmonary hypertension
Researchers have developed a simple, noninvasive way to measure right ventricular function in the heart to predict survival of adults who suffer from pulmonary hypertension.
Amias® (candesartan cilexetil), an antihypertensive drug, now shows clear benefits in symptomatic heart failure
Amias® (candesartan cilexetil), an antihypertensive drug, now shows clear benefits in symptomatic heart failure CHARM Study Programme demonstrates that Amias® saves lives and reduces hospitalisation in heart failure, irrespective of background therapy European Society of Cardiology, Vienna, 31st August 2003 - Exciting results from the largest study of an angiotensin receptor blocker (ARB) in the treatment of heart failure - the CHARM (Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity) Study Programme - were presented today revealing that Amias (candesartan cilexetil) reduces cardiovascular deaths and hospital admissions, irrespective of background therap
HEART FAILURE UNDERDIAGNOSED IN UK PRIMARY CARE (pp 432, 439)
A UK study published in this week’s issue of THE LANCET suggests that heart failure is more common than previously thought. New strategies involving the assessment of left-ventricular function in patients with suspected heart failure could lead to more successful treatment. An estimated 120,000 patients are admitted to hospital every year in the UK with heart disease. The disorder can be effectively treated if accurately diagnosed; however, accurate data for prevalence rates for heart failure due to various causes, and for left-ventricular systolic dysfunction (LVSD) in all adults are unavailable. Richard Hobbs and colleagues from the University of Birmingham, UK, did a population stu
NEW DRUG TREATMENT COULD PROVIDE LONG-TERM BENEFIT FOR HEART-ATTACK PATIENTS (p 1385)
Patients with acute myocardial infarction (heart attack), complicated by left-ventricular systolic dysfunction, could benefit from the ß-blocker carvedilol, conclude authors of a study in this week's issue of THE LANCET. In a randomised, placebo-controlled trial, this drug reduced the frequency of death from all causes, death from cardiovascular disease, and prevented the recurrence of non-fatal heart attacks. The beneficial effects of ß-blockers on long-term outcome after acute myocardial infarction were shown before the introduction of thrombolysis and angiotensin-converting-enzyme (ACE) inhibitors. Generally, the patients recruited to these trials were at low risk: few had heart fai
More Systolic Dysfunction Current Events and Systolic Dysfunction News Articles
| © 2009 BrightSurf.com |